CMS modified NCD 86 for chelation therapy, effective March 7, 2026. EDTA chelation therapy for atherosclerosis remains non-covered under Medicare — and the updated policy makes clear that billing under alternative terminology won't get you paid either.
The Centers for Medicare & Medicaid Services updated its chelation therapy coverage policy under NCD 86 on March 7, 2026. The policy covers EDTA chelation therapy used for the treatment or prevention of atherosclerosis. The policy does not list specific CPT or HCPCS codes, but the coverage determination is unambiguous: this service is experimental and non-covered under Medicare. If your billing team is submitting — or considering submitting — claims for EDTA chelation therapy under any diagnosis code or clinical terminology, stop now and read this first.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Chelation Therapy for Treatment of Atherosclerosis |
| Policy Code | NCD 86 |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | High — blanket non-coverage with explicit denial instructions for variant billing terms |
| Specialties Affected | Internal medicine, cardiology, integrative medicine, naturopathic and alternative medicine practices |
| Key Action | Audit any active orders or scheduled services for EDTA chelation therapy and cease Medicare billing immediately |
CMS Chelation Therapy Coverage Criteria and Medical Necessity Requirements 2026
The CMS chelation therapy coverage policy under NCD 86 is about as clear as Medicare gets: there is no covered indication. EDTA chelation therapy for the treatment or prevention of atherosclerosis does not meet medical necessity standards under Medicare. Full stop.
CMS states that no widely accepted rationale explains any beneficial effects from this therapy. Its safety is questioned. Its clinical effectiveness has never been established by well-designed, controlled clinical trials. Those three strikes together — mechanism unproven, safety unverified, efficacy undemonstrated — put this squarely in the experimental category.
This is not a "coverage with limitations" situation. There are no qualifying diagnosis codes that unlock reimbursement. There is no prior authorization pathway that opens access. No documentation strategy turns this into a covered service. The coverage policy is a blanket denial.
That matters for medical necessity documentation purposes. Even if a provider has detailed clinical records supporting a patient's cardiovascular risk and a compelling rationale for chelation, none of that documentation changes the outcome. CMS has made a national coverage determination. Individual Medicare Administrative Contractor (MAC) discretion doesn't apply here the way it does under a local coverage determination (LCD). NCD 86 applies to all Medicare claims, nationwide.
CMS Chelation Therapy Exclusions and Non-Covered Indications
Here's where the March 7, 2026 update gets operationally important for your billing team. The policy doesn't just deny EDTA chelation therapy billed as atherosclerosis treatment. It explicitly calls out variant terminology and requires denials under those terms as well.
Specifically, the updated policy flags three situations your billing team needs to recognize:
Chemoendarterectomy. Some providers and practice management systems use "chemoendarterectomy" as an alternative term for EDTA chelation therapy. CMS knows this. The policy names it directly. Claims using this terminology should be denied under NCD 86.
Arteriosclerosis and calcinosis diagnoses. Providers may bill chelation therapy using a diagnosis of arteriosclerosis or calcinosis rather than atherosclerosis. CMS instructs that these claims also fall under NCD 86's denial criteria. Swapping the diagnosis code does not change the coverage status.
Any variant terminology. The policy uses the phrase "such variant terms" — which signals that CMS expects billers and reviewers to apply judgment. If a claim walks like chelation therapy and talks like chelation therapy, it gets denied like chelation therapy.
This is a meaningful operational detail. Claim denial under NCD 86 isn't limited to claims that say "EDTA chelation therapy for atherosclerosis" in black and white. Your billing review process needs to flag the service itself, regardless of how it's coded or described.
The real issue here is that alternative medicine practices sometimes use billing terminology that obscures what's actually being delivered. CMS is ahead of that. The updated policy language is a direct response to that pattern. Train your coders and front-end billing staff to recognize chelation therapy by what's in the clinical notes — not just by what's on the encounter form.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| EDTA chelation therapy for atherosclerosis treatment | Not Covered — Experimental | No specific codes listed in NCD 86 | Denied under NCD 86 regardless of clinical documentation |
| EDTA chelation therapy for atherosclerosis prevention | Not Covered — Experimental | No specific codes listed in NCD 86 | Prevention indications carry same non-coverage status as treatment |
| Chelation therapy billed as chemoendarterectomy | Not Covered | No specific codes listed in NCD 86 | CMS explicitly flags this terminology — deny under NCD 86 |
| Chelation therapy billed under arteriosclerosis diagnosis | Not Covered | No specific codes listed in NCD 86 | Variant diagnosis does not change coverage status |
| Chelation therapy billed under calcinosis diagnosis | Not Covered | No specific codes listed in NCD 86 | Deny under NCD 86 per policy instructions |
CMS Chelation Therapy Billing Guidelines and Action Items 2026
The effective date of March 7, 2026 is already behind us. If your practice or revenue cycle team hasn't reviewed chelation therapy billing in light of this updated policy, do it now. Here's what to do.
| # | Action Item |
|---|---|
| 1 | Audit your active patient schedules and order sets. Pull any scheduled or recurring EDTA chelation therapy appointments for Medicare patients. These services will not receive reimbursement. Continuing to bill them creates claim denial exposure and potential overpayment liability. |
| 2 | Search your charge capture for variant terminology. Run a query for "chemoendarterectomy," "arteriosclerosis infusion therapy," and "EDTA" in your charge master, superbill, and order sets. If any of these appear in ways that could be submitted to Medicare, flag them for review before the next billing cycle. |
| 3 | Brief your coders on NCD 86's explicit denial language. Coders need to understand that this isn't a situation where clinical documentation can support a covered claim. No amount of medical necessity documentation overcomes a national coverage determination. The billing guidelines here are simple: don't bill Medicare for this service. |
| 4 | Review any outstanding Medicare claims for chelation therapy. If claims were submitted after March 7, 2026, expect denials. If claims were submitted before that date and are still pending, check whether NCD 86's prior version carried the same non-coverage stance — it did. The experimental designation and denial language have been in place for years. The March 2026 modification updated and reinforced the policy language; it did not create a new non-coverage determination from scratch. |
| 5 | Evaluate patient financial responsibility disclosures. If your practice offers EDTA chelation therapy as a cash-pay service, make sure patients receive a clear Advance Beneficiary Notice (ABN) before treatment. Medicare patients have the right to know this service won't be covered before they commit to payment. This is both a compliance requirement and a patient relations issue. |
| 6 | Cross-reference NCD 20.22. CMS cross-references this policy to section 20.22, which covers chelation therapy in a different clinical context. If your practice bills chelation therapy for any indication — not just atherosclerosis — verify that the specific indication and clinical context are reviewed against both NCD 86 and the cross-referenced section. If you're uncertain how this applies to your patient mix, talk to your compliance officer before submitting any new claims. |
The pattern here is familiar if you've watched CMS policy updates on experimental therapies over the years. The agency periodically reinforces non-coverage language for services that remain outside mainstream clinical practice. This is the same playbook CMS used when it tightened language around unproven cardiovascular interventions in prior cycles. The mechanism is the same: explicit naming of workaround terminology, clear denial instructions, and no exceptions pathway.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Chelation Therapy Under NCD 86
Policy Statement on Codes
NCD 86 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is itself a notable data point for chelation therapy billing purposes. The absence of codes doesn't create ambiguity about coverage — it reflects the fact that the non-coverage determination applies to the service itself, regardless of how it's coded.
In practice, chelation therapy may appear in claims under various procedure and infusion codes depending on how the service is described. CMS's approach here is to deny based on the nature of the service and the clinical context, not to publish a specific code-level denial list. That puts more responsibility on your billing team's clinical coding judgment — and on your coders' ability to recognize this therapy across different documentation formats.
What This Means for Chelation Therapy Billing
Because no specific codes are listed in the policy, your billing team cannot rely on a simple code-level edit to catch these claims. The denial logic lives at the service description level, not the code level. Build your edits and claim scrubbing rules around:
- Clinical documentation containing "chelation," "EDTA," or "chemoendarterectomy"
- Infusion services ordered in the context of cardiovascular or atherosclerotic diagnoses
- Any claim where the encounter notes reference heavy metal removal for cardiovascular benefit
This is a place where close coordination between your coders and your clinical documentation reviewers pays off. If your billing team can't see the clinical notes, they can't catch these claims before submission.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.